Scheduling, administration, biomarkers, and practical guidance.
10-30 day cycles. Requires clinical setting for IV administration. Experimental dose reserved for acute neurological events under medical supervision.
10-14 day cycles. Mandatory 1-2 week off-cycle between courses. Higher concentration reserved for acute neurotrauma contexts.
10-30 day cycles. Mandatory 1-2 week off-cycle between courses. Start at lower dose to assess tolerability.
6-12 week cycles. Oral for systemic/GI effects; SubQ for targeted tissue repair. FDA Category 2 — sourcing restricted.
4-8 week cycles. Mechanism of action disputed (primary papers retracted April 2025). Use with extreme caution and informed consent.
4-6 week cycles. BDNF-elevating effects may be disease-context dependent. Monitor mood and cognition throughout.
Semax is mildly stimulating via dopaminergic and BDNF pathways. Evening dosing may disrupt sleep architecture. Second dose no later than early afternoon.
Anxiolytic without sedation — can be taken AM for baseline anxiety reduction. Avoid late evening as GABAergic modulation may paradoxically increase alertness in some users.
Neurotrophic infusion is mildly activating. Morning administration aligns with peak cortisol and natural neuroplasticity windows. Monitor for 30 minutes post-infusion.
BPC-157's tissue repair signalling is not strongly circadian-dependent, but split dosing maintains more consistent plasma levels. Take 30 minutes before breakfast and 2 hours after dinner.
Threonate form crosses BBB and supports synaptic plasticity consolidation during sleep. Mild relaxation effect complements sleep onset. Separate from any calcium-containing supplements by 2 hours.